Stocks and Investing
Stocks and Investing
Thu, August 6, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Robert Burns Maintained (ATRA) at Strong Buy with Increased Target to $650 on, Aug 6th, 2020
Robert Burns of HC Wainwright & Co., Maintained "Atara Biotherapeutics, Inc." (ATRA) at Strong Buy with Increased Target from $625 to $650 on, Aug 6th, 2020.
Robert has made no other calls on ATRA in the last 4 months.
There are 2 other peers that have a rating on ATRA. Out of the 2 peers that are also analyzing ATRA, 1 agrees with Robert's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Anupam Rama of "JP Morgan" Maintained at Hold with Increased Target to $575 on, Tuesday, May 12th, 2020
This is the rating of the analyst that currently disagrees with Robert
- Yigal Nochomovitz of "Citigroup" Upgraded from Hold to Strong Buy on, Thursday, April 23rd, 2020